Reiner Siebert - Biography#

Reiner Siebert, born in 1968 in Hagen (Germany), graduated from University of Essen Medical School in 1996. He performed his clinical training at the Institute of Human Genetics in Kiel and obtained his board certification as specialized Human Geneticist in 2004. He has been continuously practicing as Human Geneticist in Kiel and since 2016 in Ulm (Germany) being Head of the Clinical Genetics services at Kiel and Ulm University Medical Centers, respectively, since 2006. Academically, Reiner Siebert earned his MD doctoral degree in 1997 from the University of Essen and his habilitation in Human Genetics from the University of Kiel in 2001. After being Full Professor and Director of the Institute of Human Genetics at Kiel University for ten years he relocated in 2016 to Ulm University where he is currently Full Professor and Director of the Institute of Human Genetics.

Reiner Siebert’s research focusses on genetic and epigenetic mechanisms of human normal and disease development and the identification of biomarkers. His special interest is in the field of somatic (epi)genetics with a focus but not restricted to cancer, and here particularly lymphomas and rhabdoid tumors. Among others, Reiner Siebert has contributed to the Human Genome mapping consortium, coordinated the German ICGC MMML-seq project as part International Cancer Genome Consortium (ICGC) and lead the work package on normal and neoplastic B- and T-cells within the EU-funded International Human Epigenome Consortium (IHEC) project BLUERPINT. He coordinated the genetics group of the German Molecular Mechanisms in Malignant Lymphoma consortium, is Deputy Director of the Center of Rare Diseases Ulm, Fellow at the Center of Integrated Quantum Science and Technology and PI at the International Graduate School in Molecular Medicine Ulm.

Reiner serves as Section Editor for lymphoma of the journal Leukemia and on the Editorial Board of Genes, Chromosomes & Cancer and Medizinische Genetik. He has been appointed as senior advisor for the revised 4th edition and expert member to the editorial board for the 5th edition of the WHO Blue Books for the classification of Heamatolymphoid Tumors volume.